Search

Sodium lauryl sulfate

It is also used in creams and pastes to properly disperse the ingredients and as research tool in protein biochemistry. SLS also has some microbicidal activity. … SLS lowers surface tension of aqueous solutions and is used as fat emulsifier, wetting agent, and detergent in cosmetics, pharmaceuticals and toothpastes.

Iopromide

[A260751] Approved by the FDA in 1995 and Health Canada in 1994 under the brand name ULTRAVIST, iopromide is used in radiological diagnosis, including, but not limited to, intra-arterial digital subtraction … it is still deemed to have a favorable safety profile, with only 0.7% of patients in a 2 years study experiencing adverse events.

Calcium phosphate dihydrate

Omidenepag isopropyl

[A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl. … [A253263,A253268] Prostanoid FP receptor agonists (FP agonists), such as [latanoprost], are part of the first-line therapy for ocular hypertension and primary open-angle glaucoma; however, not all patients

Thrombin alfa

Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line. … Thrombin Alfa is identical in amino acid sequence and structurally similar to naturally occurring human thrombin.

Streptococcus pneumoniae type 9n capsular polysaccharide antigen

It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 9n capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 9n of *Streptococcus pneumoniae*

Darvadstrocel

[L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication. … It is indicated for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal Crohn’s disease when fistulas have shown an inadequate response to at least one

Daclatasvir

The same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis. … According to 2017 American Association for the Study of Liver Diseases (AASLD), 60mg of daclatasvir is recommended with 400mg [DB08934] for genotype 1a/b patients with or without cirrhosis as second-line

Ethiodized oil

Ethiodized oil is used by injection as a radio-opaque contrast agent. The composition of the oil is comprised of iodine combined with ethyl esters of fatty acids of poppyseed oil. … And although these esters are primarily as ethyl monoiodostearate and ethyl diiodostearate, the actual, specific structure is unknown.

Sparsentan

[L45300,L45315] In September 2024, it was granted full approval for an expanded indication. … [L51419] Sparsentan was initially developed for the treatment of hypertension;[A257340] however, it has shown to be efficient in the reduction of proteinuria in patients with IgAN and focal segmental glomerulosclerosis